department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Xifaxan · pharmadog

pharmadog
drugs
Xifaxan

drug

patient view →

rifaximin

Marketedupdated 2mo ago

by Salix Pharmaceuticals Ltd

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Xifaxan

generic

rifaximin

indication

Hepatic Encephalopathy

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 2, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (24)

Oct 2, 2029method-of-use (U-1481)US 86425733.2y
Oct 2, 2029method-of-use (U-1481)US 89693983.2y
Jul 24, 2029method-of-use (U-1481)US 103148283.0y
Jul 24, 2029method-of-use (U-2579)US 103353973.0y
Jul 24, 2029method-of-use (U-2579)US 107096943.0y
Jul 24, 2029method-of-use (U-1121)US 79281153.0y
Jul 24, 2029method-of-use (U-1562)US 88290173.0y
Jul 24, 2029method-of-use (U-1481)US 89462523.0y
Jul 24, 2029method-of-use (U-1481)US 94211953.0y
Jul 24, 2029method-of-use (U-1994)US 96298283.0y
Feb 26, 2029method-of-use (U-2644)US 104563842.6y
Feb 26, 2029method-of-use (U-2643)US 107656672.6y
Feb 26, 2029method-of-use (U-3512)US 115649122.6y
Feb 26, 2029method-of-use (U-3706)US 117795712.6y
Sep 2, 2027compositionUS 81931961.2y
Sep 2, 2027compositionUS 81931961.2y
Feb 27, 2026method-of-use (U-1708)US 10703763
Feb 27, 2026method-of-use (U-2848)US 10703763
Feb 27, 2026formulationUS 8518949
Feb 27, 2026formulationUS 8518949
Feb 27, 2026compositionUS 8741904
Feb 27, 2026compositionUS 8741904
Feb 27, 2026formulationUS 9271968
Feb 27, 2026formulationUS 9271968

🐶 often sniffed alongside

top 2

tagApproval2 co-mentions · 1 sources
tagSmall Molecule1 co-mentions · 1 sources

Trials studying rifaximin

phase2Rifaximin SSD in Dementia Trialrecruitingn=20
phase4Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhearecruitingn=54
phase3Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosisactive not recruitingn=466
phase2Microbiota Intervention to Change the Response of Parkinson's Diseasesuspendedn=86
phase3Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosisactive not recruitingn=524
phase4Rifaximin for the Secondary Prevention of Recurrent Pouchitisrecruitingn=16
phase3Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascitescompletedn=160
phase4Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactuloserecruitingn=238

more trials →